Leukocytapheresis for the treatment of IBD
Authors:
- Ingvar BjarnasonIBIngvar Bjarnason
- 29 July 2008
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Gastroenterology & Hepatology
- Vol. 5 (9) , 509-516
Abstract
Leukocytapheresis is a controversial nonpharmacologic treatment for IBD, in which white blood cells--the effector cells of the inflammatory process--are mechanically removed from the circulation. Current controversy centers on the uncontrolled nature of the leukocytapheresis trials performed and their use of different outcome measures in patient groups that have very variable disease activity and severity. Nonetheless, the efficacy data obtained are generally quite consistent: an excellent response (remission >80%) has been achieved in corticosteroid-naïve patients with ulcerative colitis and an average remission rate of more than 50% has been achieved in patients who have steroid-dependent or refractory ulcerative colitis. Interestingly, the largest randomized, double-blind, sham-controlled study of granulocyte-monocyte apheresis in patients with moderate to severe ulcerative colitis failed to demonstrate efficacy for the induction of clinical remission or response. Regardless, leukocytapheresis seems to be remarkably safe. The precise positioning of leukocytapheresis in the treatment of ulcerative colitis is uncertain at present and will vary according to geography and patient preference for a safe, nonpharmacologic treatment. Further efficacy studies are required to assess what the optimal number and frequency of treatments is, in addition to the need for head-to-head comparisons with established drugs.Keywords
This publication has 56 references indexed in Scilit:
- Treatment of inflammatory bowel disease: A review of medical therapyWorld Journal of Gastroenterology, 2008
- Innovative therapeutics for inflammatory bowel diseaseWorld Journal of Gastroenterology, 2007
- Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective studyWorld Journal of Gastroenterology, 2006
- Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitisWorld Journal of Gastroenterology, 2006
- Natalizumab Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitisWorld Journal of Gastroenterology, 2005
- Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active‐surveillance reportArthritis & Rheumatism, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- A critical approach to new forms of treatment of Crohn's disease and ulcerative colitisAlimentary Pharmacology & Therapeutics, 2002
- Treatment of Crohn's disease by lymphocyte apheresis: A randomized controlled trialGastroenterology, 1994